JP2022502405A5 - - Google Patents
Info
- Publication number
- JP2022502405A5 JP2022502405A5 JP2021516916A JP2021516916A JP2022502405A5 JP 2022502405 A5 JP2022502405 A5 JP 2022502405A5 JP 2021516916 A JP2021516916 A JP 2021516916A JP 2021516916 A JP2021516916 A JP 2021516916A JP 2022502405 A5 JP2022502405 A5 JP 2022502405A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- peaks
- solid
- form according
- xrpd
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024104074A JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736979P | 2018-09-26 | 2018-09-26 | |
| US62/736,979 | 2018-09-26 | ||
| PCT/US2019/053076 WO2020069068A1 (en) | 2018-09-26 | 2019-09-26 | Polymorphic compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104074A Division JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502405A JP2022502405A (ja) | 2022-01-11 |
| JP2022502405A5 true JP2022502405A5 (https=) | 2022-10-04 |
| JPWO2020069068A5 JPWO2020069068A5 (https=) | 2022-10-04 |
Family
ID=69885558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516916A Pending JP2022502405A (ja) | 2018-09-26 | 2019-09-26 | 多形化合物およびその使用 |
| JP2024104074A Pending JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104074A Pending JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10765693B2 (https=) |
| EP (1) | EP3856741A4 (https=) |
| JP (2) | JP2022502405A (https=) |
| KR (1) | KR20210093864A (https=) |
| CN (1) | CN112930349A (https=) |
| AU (1) | AU2019346585B2 (https=) |
| BR (1) | BR112021005290A2 (https=) |
| CA (1) | CA3113250A1 (https=) |
| EA (1) | EA202190576A1 (https=) |
| IL (1) | IL281718A (https=) |
| MX (1) | MX2021003515A (https=) |
| WO (1) | WO2020069068A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| IL276358B2 (en) | 2018-02-09 | 2024-11-01 | Astrocyte Pharmaceuticals Inc | Compounds and methods for treating addiction and related disorders |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| MX2023014655A (es) | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
| WO2023091791A1 (en) * | 2021-11-22 | 2023-05-25 | Astrocyte Pharmaceuticals, Inc. | Methods of treating neurological and cardiovascular conditions |
| WO2024097387A1 (en) * | 2022-11-03 | 2024-05-10 | Astrocyte Pharmaceuticals, Inc. | Compositions for intravenous administration |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69428536T2 (de) | 1993-07-13 | 2002-06-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A3 -adenosin -rezeptor agonisten |
| US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7087589B2 (en) * | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| JP4012070B2 (ja) | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用 |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| US7557092B2 (en) | 2002-11-21 | 2009-07-07 | University Of Utah Research Foundation | Purinergic modulation of smell |
| GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
| JP2008512457A (ja) | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| WO2007139775A2 (en) | 2006-05-23 | 2007-12-06 | University Of Connecticut | N-methanocarba derivatives to treat cardiac diseases |
| WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
| JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
| US20100256086A1 (en) | 2007-11-23 | 2010-10-07 | Bar-Ilan Univetrsity | Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof |
| CA2720037C (en) | 2008-03-31 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 adenosine receptor-selective agonists |
| WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2429565A4 (en) | 2009-04-15 | 2012-11-14 | Univ California | NEURONIC OR NERVE PEPTIDES AND APTAMERS |
| WO2011068978A1 (en) | 2009-12-02 | 2011-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives and dendrimer conjugates thereof |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| ES2654363T3 (es) | 2010-02-22 | 2018-02-13 | University Of Connecticut | Derivados de AMP para tratar enfermedades cardíacas |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
| US20140241990A1 (en) | 2011-09-30 | 2014-08-28 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
| EA034135B9 (ru) | 2013-03-13 | 2020-04-10 | Тафтс Юниверсити | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов |
| WO2015080940A1 (en) | 2013-11-27 | 2015-06-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| EP3253388A4 (en) | 2015-02-04 | 2018-11-21 | Baker Heart and Diabetes Institute | A method of treatment and compounds for use therein |
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| IL276358B2 (en) * | 2018-02-09 | 2024-11-01 | Astrocyte Pharmaceuticals Inc | Compounds and methods for treating addiction and related disorders |
-
2019
- 2019-09-26 EA EA202190576A patent/EA202190576A1/ru unknown
- 2019-09-26 US US16/583,570 patent/US10765693B2/en active Active
- 2019-09-26 EP EP19867559.7A patent/EP3856741A4/en active Pending
- 2019-09-26 MX MX2021003515A patent/MX2021003515A/es unknown
- 2019-09-26 CA CA3113250A patent/CA3113250A1/en active Pending
- 2019-09-26 AU AU2019346585A patent/AU2019346585B2/en active Active
- 2019-09-26 CN CN201980071019.6A patent/CN112930349A/zh active Pending
- 2019-09-26 BR BR112021005290-9A patent/BR112021005290A2/pt unknown
- 2019-09-26 WO PCT/US2019/053076 patent/WO2020069068A1/en not_active Ceased
- 2019-09-26 KR KR1020217012486A patent/KR20210093864A/ko not_active Ceased
- 2019-09-26 JP JP2021516916A patent/JP2022502405A/ja active Pending
-
2020
- 2020-07-28 US US16/940,451 patent/US11324769B2/en active Active
-
2021
- 2021-03-22 IL IL281718A patent/IL281718A/en unknown
-
2024
- 2024-06-27 JP JP2024104074A patent/JP2024114885A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502405A5 (https=) | ||
| JP2022088642A5 (https=) | ||
| Walker | Prion-like mechanisms in Alzheimer disease | |
| JP2009509921A5 (https=) | ||
| Wallace et al. | Drug targets for cognitive enhancement in neuropsychiatric disorders | |
| AU2016299486B2 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| ES2617881T5 (es) | Dihidrato de compuesto de benzotiofeno y proceso de producción del mismo | |
| CA2560047A1 (en) | Substituted imidazoles and their use as opioid receptor modulators | |
| JP6215971B2 (ja) | てんかん又はてんかん−関連症侯群の予防又は治療用フェニルアルキルカルバメート化合物｛ｐｈｅｎｙｌａｌｋｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｅｐｉｌｅｐｓｙｏｒｅｐｉｌｅｐｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅ｝ | |
| JP2013544277A5 (https=) | ||
| ZA200601324B (en) | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | |
| JP2019525939A5 (https=) | ||
| JP2019501935A5 (https=) | ||
| ME01903B (me) | Hetrociklički sulfonamidi, njihova upotreba i farmaceutski pripravci | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| JP2010529081A5 (https=) | ||
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| JPWO2020069068A5 (https=) | ||
| FI3494119T3 (fi) | Yhdisteitä ja koostumuksia ja niiden käyttötapoja | |
| KR102854594B1 (ko) | 신규한 화합물 | |
| JP2016506939A5 (https=) | ||
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| GEAP202516743A (en) | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 | |
| CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity | |
| Behl et al. | Exploring the potential role of rab5 protein in endo-lysosomal impairment in Alzheimer’s disease |